Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial-论文-万方医学网

首页> > Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

导出原文传递

翻译打印收藏纠错

第一作者： Weinstock-Guttman, Bianca

作者： Weinstock-Guttman, Bianca ^[1] ; Bermel, Robert ^[2] ; Cutter, Gary ^[3] ; Freedman, Mark S. ^[4] ; Leist, Thomas P. ^[5] ; Ma, Xiaoye ^[6] ; Kile, Deidre ^[7] ; Musch, Bruno ^[8] ; Reder, Anthony T. ; Wolinsky, Jerry S. ; CHORDS Investigators

作者单位： SUNY Buffalo ^[1] Mellen Ctr MS,Cleveland Clin ^[2] Univ Alabama Birmingham ^[3] Dept Med,Univ Ottawa ^[4] Thomas Jefferson Univ ^[5] Genentech Inc ^[6] Univ Chicago ^[7] McGovern Med Sch,Univ Texas Hlth Sci Ctr Houston UTHlth ^[8]

关键词 Multiple sclerosis switch ocrelizumab safety MRI disease progression INTERFERON BETA-1A ADHERENCE SATISFACTION TIME

发布时间 2022-07-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

相似文献

同项目论文

相关期刊

检索历史 清除

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

相似文献

同项目论文

相关期刊

检索历史清除